Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03289195 · ClinicalTrials.gov registry record · NA

Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer

A NA study of Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
NA
Development phase
31
Enrollment target
7
Study locations

NCT03289195: Active NA study of Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT03289195 is a NA study of Breast Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 31 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03289195, a NA study of Breast Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
31 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to test the ability of a breast MRI biopsy to accurately diagnose a complete tumor response to the neoadjuvant chemotherapy (NAC) that the patient just finished. Numerous studies have shown that MRI has the highest accuracy for diagnosing a complete tumor response. The investigator wants to see if in a certain group of women who's breast cancer is no longer visible on the post-treatment MRI that the biopsy specimens from a MRI guided biopsy will accurately diagnose a complete tumor response to treatment which may in the future make breast surgery unnecessary in some women.

Primary Outcome

In this context NPV is defined as the number of true negatives (biopsy negative, i.e., no disease found on the percutaneous biopsy and pCR) divided by the number of all biopsy negatives. While NPV is of primary interest we will also estimate positive predictive value, sensitivity, and specificity of the biopsy.

Conditions Studied

Interventions

  • PROCEDURE MRI Biopsy

Study Locations (7)

New York

  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (All Protocol Activities) - Rockville Centre

New Jersey

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2017-09-18
Est. Completion 2026-09
Phase NA
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT03289195 still lists

NCT03289195 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRI Biopsy is the first listed.

NCT03289195 lists 7 locations in 2 states (New York, New Jersey).

Frequently Asked Questions

What is clinical trial NCT03289195 about?

NCT03289195 is a clinical study titled "Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer". The purpose of this study is to test the ability of a breast MRI biopsy to accurately diagnose a complete tumor response to the neoadjuvant chemotherapy (NAC) that the patient just finished. Numerous studies have shown that MRI has the highest accuracy for diagnosing a complete tumor response. The i...

What is the current status of trial NCT03289195?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 31 participants. The study started on 2017-09-18. Estimated completion is 2026-09.

What conditions does trial NCT03289195 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT03289195?

The interventions under investigation include: MRI Biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT03289195?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03289195 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03289195's enrollment target sits among peer trials

31 948th of 1224 higher than 271 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03289195, the US trial registry maintained by the National Library of Medicine. NCT03289195 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.